Antonio Llombart-Cussac

Articles by Antonio Llombart-Cussac

TIP137 ADELA: A Double-blind, Placebo-Controlled, Randomized Phase 3 Trial of Elacestrant + Everolimus Versus Elacestrant + Placebo in ER+/HER2- Advanced Breast Cancer (aBC) Patients With ESR1-Mutated Tumors Progressing on Endocrine Therapy (ET) + CDK4/6i

ByAntonio Llombart-Cussac,José Manuel Pérez-García,Elena Lopez-Miranda,Cristina Saavedra,Vicente Carañana,Isabel Blancas,Carmen Hinojo-González,Alfonso Cortes-Salgado,Elena Galve,Rui Rui Zhang,Miguel Sampayo-Cordero,Daniel Alcalá-López,Juliana Carvalho-Santos,Olga Boix,Ana Garrido,Carlos H Barrios,Giuseppe Curigliano,Rupert Bartsch,Anne Claire Hardy Bessard,Tomer Wasserman,Javier Cortés, MD

30 Imlunestrant, an Oral Selective Estrogen Receptor Degrader, as Monotherapy and Combined With Abemaciclib, for Patients with ER+, HER2– Advanced Breast Cancer, Pretreated With Endocrine Therapy: Results of the Phase 3 EMBER-3 Trial

ByAarti Chawla,Komal Jhaveri,Patrick Neven, MD, PhD,Monica Lis Casalnuovo,Sung-Bae Kim,Eriko Tokunaga,Philippe Aftimos,Cristina Saura,Joyce A. O’Shaughnessy,Nadia Harbeck, MD, PhD,Lisa A. Carey, MD,Guiseppe Curigliano,Antonio Llombart-Cussac,Elgene Lim, MBBS, FRACP, PhD,María de la Luz García Tinoco,Joohyuk Sohn,Andre Mattar,Qingyuan Zhang,Chiun-Sheng Huang,Chih-Chiang Hung,Jorge Luis Martinez Rodriguez,Manuel Ruiz Borrego

TPS 43 ADELA: A Double-Blind, Placebo-Controlled, Randomized Phase 3 Trial of Elacestrant + Everolimus vs Elacestrant + Placebo in ER+/HER2– Advanced Breast Cancer Patients With ESR1-Mutated Tumors Progressing on Endocrine Therapy

ByAntonio Llombart-Cussac,José Manuel Pérez-García,Elena Lopez-Miranda,Rui Rui Zhang,Miguel Sampayo-Cordero,Juliana Carvalho-Santos,Olga Boix,Marta Beltran,Carlos Barrios,Guiseppe Curigliano,Rupert Bartsch,Anne Clair Hardy Bessard,Anna Compagnoni,Kathy Puyana Theall,Thomas Buechele,Tomer Wasserman,Javier Cortés, MD

Latest Updated Articles